Tau-targeting Alzheimer's treatment, HMTM, moving toward regul...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SINGAPORE, June 1, 2022 /PRNewswire-AsiaNet/ -- - LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research- Safety profile is favourable and consistent with previous HM...
Authors: LATEST ASIANET NEWS RELEASES